Tango Therapeutics, Inc. (TNGX) KPIs and segments
Close on Nov 17, 2026Market cap $3.73BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Tango Therapeutics's business
Tango Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Collaboration Revenue($M) | 0 | 53.8 | 3.18 | 5.39 | 4.12 | 11.6 | 7.78 | 6.47 | 5.43 | 10.7 | 9.60 | 6.41 | |
License Revenue($M) | 0 | 0 | 12.1 | 0 | 0 | 5 | |||||||
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-03-05.
See a number that looks wrong?